Targeting the medulloblastoma: a molecular-based approach.
Journal
Acta bio-medica : Atenei Parmensis
ISSN: 2531-6745
Titre abrégé: Acta Biomed
Pays: Italy
ID NLM: 101295064
Informations de publication
Date de publication:
30 06 2020
30 06 2020
Historique:
received:
30
05
2020
accepted:
01
06
2020
entrez:
2
7
2020
pubmed:
2
7
2020
medline:
29
6
2021
Statut:
epublish
Résumé
The lack of success of standard therapies for medulloblastoma has highlighted the need to plan a new therapeutic approach. The purpose of this article is to provide an overview of the novel treatment strategies based on the molecular characterization and risk categories of the medulloblastoma, also focusing on up-to-date relevant clinical trials and the challenges in translating tailored approaches into clinical practice. An online search of the literature was carried out on the PubMed/MEDLINE and ClinicalTrials.gov websites about molecular classification of medulloblastomas, ongoing clinical trials and new treatment strategies. Only articles in the English language and published in the last five years were selected. The research was refined based on the best match and relevance. A total 58 articles and 51 clinical trials were analyzed. Trials were of phase I, II, and I/II in 55%, 33% and 12% of the cases, respectively. Target and adoptive immunotherapies were the treatment strategies for newly diagnosed and recurrent medulloblastoma in 71% and 29% of the cases, respectively. Efforts are focused on the fine-tuning of target therapies and immunotherapies, including agents directed to specific pathways, engineered T-cells and oncoviruses. The blood-brain barrier, chemoresistance, the tumor microenvironment and cancer stem cells are the main translational challenges to be overcome in order to optimize medulloblastoma treatment, reduce the long-term morbidity and increase the overall survival.
Sections du résumé
BACKGROUND
The lack of success of standard therapies for medulloblastoma has highlighted the need to plan a new therapeutic approach. The purpose of this article is to provide an overview of the novel treatment strategies based on the molecular characterization and risk categories of the medulloblastoma, also focusing on up-to-date relevant clinical trials and the challenges in translating tailored approaches into clinical practice.
METHODS
An online search of the literature was carried out on the PubMed/MEDLINE and ClinicalTrials.gov websites about molecular classification of medulloblastomas, ongoing clinical trials and new treatment strategies. Only articles in the English language and published in the last five years were selected. The research was refined based on the best match and relevance.
RESULTS
A total 58 articles and 51 clinical trials were analyzed. Trials were of phase I, II, and I/II in 55%, 33% and 12% of the cases, respectively. Target and adoptive immunotherapies were the treatment strategies for newly diagnosed and recurrent medulloblastoma in 71% and 29% of the cases, respectively.
CONCLUSION
Efforts are focused on the fine-tuning of target therapies and immunotherapies, including agents directed to specific pathways, engineered T-cells and oncoviruses. The blood-brain barrier, chemoresistance, the tumor microenvironment and cancer stem cells are the main translational challenges to be overcome in order to optimize medulloblastoma treatment, reduce the long-term morbidity and increase the overall survival.
Identifiants
pubmed: 32608377
doi: 10.23750/abm.v91i7-S.9958
pmc: PMC7975825
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
79-100Références
Science. 2009 Oct 23;326(5952):572-4
pubmed: 19726788
Nat Rev Cancer. 2012 Dec;12(12):818-34
pubmed: 23175120
J Clin Oncol. 2013 Aug 10;31(23):2927-35
pubmed: 23835706
Heliyon. 2019 Nov 26;5(11):e02818
pubmed: 31844735
J Clin Oncol. 2014 Mar 20;32(9):886-96
pubmed: 24493713
J Clin Oncol. 2019 Mar 20;37(9):731-740
pubmed: 30730781
Cancer Res. 2004 Nov 1;64(21):7794-800
pubmed: 15520185
Mol Pharm. 2014 Aug 4;11(8):2755-63
pubmed: 24983928
J Immunother Cancer. 2018 Apr 30;6(1):30
pubmed: 29712574
Childs Nerv Syst. 2008 Jun;24(6):773-6
pubmed: 18369643
J Clin Neurosci. 2012 Nov;19(11):1541-4
pubmed: 22981874
Cold Spring Harb Perspect Med. 2014 Oct 01;4(10):
pubmed: 25274755
J Pediatr Endocrinol Metab. 2014 Jan;27(1-2):107-15
pubmed: 24025722
Cancer Res. 2012 Jan 1;72(1):122-32
pubmed: 22052462
PLoS One. 2012;7(10):e47109
pubmed: 23056595
Childs Nerv Syst. 2013 Apr;29(4):589-96
pubmed: 23296323
Lancet Oncol. 2004 Apr;5(4):209-18
pubmed: 15050952
Acta Neuropathol. 2016 Jun;131(6):821-31
pubmed: 27040285
J Headache Pain. 2014 Sep 01;15:57
pubmed: 25178699
Dev Med Child Neurol. 2019 Sep;61(9):1101-1107
pubmed: 31175679
Cancer Res. 2013 Dec 1;73(23):7034-42
pubmed: 24154871
Nat Rev Clin Oncol. 2014 Dec;11(12):714-22
pubmed: 25348790
J Clin Oncol. 2011 Apr 10;29(11):1408-14
pubmed: 20823417
Neuro Oncol. 2017 Sep 01;19(9):1217-1227
pubmed: 28379574
Mol Ther. 2014 May;22(5):1048-55
pubmed: 24572293
J Clin Oncol. 2006 Apr 20;24(12):1924-31
pubmed: 16567768
Mol Cell Biol. 2011 Jul;31(13):2641-52
pubmed: 21555454
Stem Cells. 2007 Oct;25(10):2524-33
pubmed: 17628016
Cancer Cell. 2014 Mar 17;25(3):393-405
pubmed: 24651015
Cancer Res. 2010 Jul 1;70(13):5618-27
pubmed: 20516124
Front Cell Dev Biol. 2019 Jan 07;6:170
pubmed: 30666305
Nature. 2017 Jul 19;547(7663):311-317
pubmed: 28726821
Nature. 2012 Aug 2;488(7409):100-5
pubmed: 22832583
Neuro Oncol. 2016 Feb;18(2):227-35
pubmed: 26188016
Cancer Sci. 2016 Jan;107(1):5-11
pubmed: 26362755
J Neurooncol. 2015 Apr;122(2):321-7
pubmed: 25557108
Cancer Cell. 2008 Aug 12;14(2):123-34
pubmed: 18691547
J Neurosurg. 1983 Apr;58(4):543-52
pubmed: 6827349
Acta Neuropathol. 2012 Apr;123(4):473-84
pubmed: 22358457
Nat Commun. 2018 Oct 8;9(1):4121
pubmed: 30297829
Acta Neuropathol. 2011 Mar;121(3):381-96
pubmed: 21267586
J Neurooncol. 2019 Nov;145(2):295-300
pubmed: 31552589
Oper Neurosurg (Hagerstown). 2018 Dec 1;15(6):E92-E93
pubmed: 29618124
Int J Mol Sci. 2018 Sep 17;19(9):
pubmed: 30227679
Nature. 2012 Aug 2;488(7409):43-8
pubmed: 22722829
Science. 2002 Aug 30;297(5586):1559-61
pubmed: 12202832
Acta Neuropathol. 2012 Apr;123(4):465-72
pubmed: 22134537
Mol Cancer. 2015 Feb 03;14:17
pubmed: 25645196
Br J Cancer. 2002 Oct 21;87(9):945-9
pubmed: 12434281
J Mol Med (Berl). 2015 Oct;93(10):1075-84
pubmed: 26350064
J Clin Oncol. 2001 Aug 1;19(15):3463-9
pubmed: 11481351
Aging (Albany NY). 2020 Jan 27;12(2):1928-1951
pubmed: 31986121
Cancer Sci. 2016 May;107(5):583-9
pubmed: 27171351
Trends Cell Biol. 2019 Jan;29(1):44-65
pubmed: 30220580
Exp Cell Res. 2015 Jul 1;335(1):135-47
pubmed: 25967525
World Neurosurg. 2019 Apr;124:e769-e778
pubmed: 30677572
Int J Pharm. 2017 Jan 30;517(1-2):168-174
pubmed: 27956195
J Pediatr Surg. 2008 Nov;43(11):1998-2003
pubmed: 18970931
Clin Cancer Res. 2008 Jul 1;14(13):4154-60
pubmed: 18593994
World Neurosurg. 2019 Dec;132:e40-e52
pubmed: 31520759
Clin Neurol Neurosurg. 2020 Feb;189:105623
pubmed: 31805490
J Neurooncol. 2012 Jan;106(1):59-70
pubmed: 21735115
Neuro Oncol. 2011 Jan;13(1):14-27
pubmed: 21075780
J Hematol Oncol. 2019 Mar 15;12(1):29
pubmed: 30876441
Nature. 2012 Aug 2;488(7409):106-10
pubmed: 22820256
Arch Dis Child. 2019 Aug;104(8):768-774
pubmed: 30948362
Brain Pathol. 2020 May;30(3):679-690
pubmed: 31799776
J Clin Oncol. 2015 Aug 20;33(24):2646-54
pubmed: 26169613
World Neurosurg. 2019 Nov;131:10-17
pubmed: 31356977
Nat Rev Clin Oncol. 2011 Jun 28;8(9):540-9
pubmed: 21709698
Acta Neuropathol. 2011 Aug;122(2):231-40
pubmed: 21681522
Cancer Cell. 2016 Apr 11;29(4):508-522
pubmed: 27050100
Ital J Pediatr. 2018 Apr 4;44(1):44
pubmed: 29618369
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Nature. 2010 Dec 23;468(7327):1095-9
pubmed: 21150899
Neuro Oncol. 2012 Jul;14(7):859-69
pubmed: 22591662
Cell. 2012 Jan 20;148(1-2):59-71
pubmed: 22265402
Turk Neurosurg. 2018;28(3):454-461
pubmed: 28481388
J Clin Oncol. 2011 Oct 10;29(29):3852-61
pubmed: 21911727
BMC Cancer. 2014 Mar 19;14:206
pubmed: 24646176
Oncotarget. 2015 Jan 20;6(2):802-13
pubmed: 25596739
Nature. 2012 Aug 2;488(7409):49-56
pubmed: 22832581